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 ABSTRACT  
 
Breast  cancer  is  second  foremost  cause of deaths  in women  caused by malignant  tumor. 
Comparing genetic profiles of cells surrounding the tumor and blood from same patient may 
reveal de‐novo  somatic aberrations  that may predispose normal  cells  to  cancer  cells. Two 
major  types  of  genetic  variations  were  discovered  in  human  genome:  single  nucleotide 
polymorphisms  (SNPs)  and  more  recently  discovered  copy  number  variations  which  are 
chromosomal  segments  ranging  from  kilobases  to megabases.  It  is  assumed  that  somatic 
cells  are  genetically  identical.  But  it  is  unknown  if  CNVs  arise  in  somatic  cells.  Somatic 
mosaicism  is  defined  as  genetic  differences  in  the  cells  of  a  single  individual which were 
developed  from one  fertilized egg. The purpose of  this study was  to  identify and compare 
copy  number  variants  in  IFNAR1  loci  of  healthy  uninvolved  margin  of  breast  tissue 
surrounding  primary  tumor  and  blood  derived‐DNA  of  breast  cancer  patients  by  using 
Illumina SNPs array‐Human660W‐Quad.  
So far, long and very rigorous research on breast cancer explains only about 10% of all cases.  
This  may  signify  unusual  complexity  of  cancer  and  discovery  of  factors  responsible  for 
progression of cancer from healthy cells.  
Illumina SNPs genotyping of blood and cells surrounding tumor  indicated the occurrence of 
changes  in the region connected to  IFNAR1 gene  loci. Variations  in  IFNAR1  loci formed the 
base for detailed investigation of expected aberrations. The amplification of DNA fragments 
and  deeper  investigations  were  performed  to  identify  and  confirm  the  differences  in 
genotype between blood and cells  surrounding  the  tumor by cloning,  restriction digestion 
and  Sanger’s  sequencing.  The  results  noticeably  confirmed  the  presence  of  somatic 
mosaicism. We have identified aberrations occurring as variable number of tandem repeats 
(VNTRs) with length of 32 nucleotides.  
Consequently, the significant progress in research on cause of cancer carries development of 
applied  technologies  (next  generation  sequencing)  that  allow  examining more  number  of 
samples in fewer instances with better precision.      
 
 
                    
 
 
 
 
 ABBREVIATIONS 
 
BAF  B Allele Frequency  
BRCA1   Breast cancer susceptibility protein 1 
BRCA2   Breast cancer susceptibility 2 
CNV  Copy Number Variation   
FISH  Fluorescent In Situ Hybridization   
IFNAR   Interferon-α/β receptor  
INF  Interferon 
JAK  Janus Family Kinases 
MMBIR  Microhomology-mediated break-induced replication 
PCR   Polymerase Chain Reaction 
SNP  Single-Nucleotide Polymorphism 
VNTR  Variable Number Tandem Repeat 
WGG  Whole Genome Genotyping 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
CONTENTS   PAGE NO 
Abstract  3 
Abbreviations 4 
Introduction  5 
Methodological background   9 
Aim  13 
Materials and methods  15 
Results 19 
Discussion 23 
Future prospects  25 
Acknowledgements  26 
References  27 
  
 
 
 
 
7 
 
INTRODUCTION  
Breast cancer is an uncontrolled growth of breast cells forming a malignant tumor. Cancer 
occurs due to mutations or abnormal changes in the genes which are responsible for growth of 
the cells. The genes in the nucleus of each cell act as a control room and regulate the growth 
of the cells  [1,2]. Cell division is a process in which new cells develop as the old cells die. 
When it comes to cell division, cancer cells break all the rules. Over time, mutations can “turn 
off or turn on’’ certain genes in a cell. These cells gain the ability to divide without control or 
order, producing a high number of cells and forming tumor. Tumors can be benign or 
malignant. Benign tumors are not cancerous and grow slowly are considered as normal cells 
and do not spread to other parts of the body. Malignant tumors are cancerous and spread to 
other parts of the body [3].  
Breast cancer is a malignant tumor either beginning in the cells of lobules or ducts. In few 
cases, breast cancer begins in the stromal tissues which includes fatty and fibrous connective 
tissues of the breast (Figure 1) [4]. 
 
Figure 1. Schematic diagram of breast with cancer (adopted from 
http://www.healthspablog.org/tag/breast-cancer/ Posted in cancer on 1 May 2009) 
Only 5-10% breast cancer is caused due to abnormality inherited from parents and 90% is due 
to genetic abnormality that occurs due to the aging process.  A primary tumor is a tumor 
growing at the site where tumor progression begins and proceeded to yield a mass of 
cancerous cells. Breast cancer tissue that has metastasized to the bone is still called as breast 
cancer. Margins, also known as margins of resection, mean the distance between the tumor 
and healthy tissue also known as uninvolved margin [5]. 
One major issue is to find connections of these changes to a certain diseases. The major 
challenge in human genetics is to identify the DNA sequence differences that distinguish 
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individuals. These differences were thought to be mostly single nucleotide polymorphism 
(SNP) changes, structural variation including duplications, deletions and inversions of large 
blocks of DNA sequence in the human genome [6, 7]. Structural variants have recently been 
linked to diseases such as asthma and analyzing these variants counts an important step in 
determining the genetic basis of diseases [8]. Approximately 5-10 % of mutations 
contributing to breast cancer are caused by the inactivation of autosomal dominant genes: the 
breast cancer susceptibility genes BRCA1 and BRCA2 [9,10] 
Copy number variation (CNV) is the number of copies of a particular gene or several genes 
in the genotype of an individual. These segments may range from one kilobase to several 
megabases in size. Humans being diploid have two copies of each autosomal region in 
autosomal chromosomes. This number could increase or decrease due to deletion or 
duplication [11]. 
CNVs occur due to de novo mutation or may be inherited. Fork stalling and template 
switching are replication missteps that recently have been proposed as mechanism for the 
cause of some CNVs [12]. However, this model was subsequently superseded by 
microhomology-mediated break-induced replication (MMBIR) [13]. 
Some genomic rearrangements such as deletions, duplications, inversions and translocations 
cause CNVs [14].  Some region-specific repeated sequences like low copy repeats are 
susceptible to such genomic rearrangements which results in CNVs [15]. CVNs can be 
identified by using cytogenetic techniques like fluorescent in situ hybridization (FISH), array 
comparative genomic hybridization and virtual karyotyping with SNP arrays. 
After the completion of the human genome project the fact that DNA copy number variation 
is a widespread and common phenomenon among humans was first uncovered. With respect 
to copy number approximately 0.4% of genomes of unrelated people typically differ.  De 
novo CNVs have been observed in identical twins who otherwise have similar genomes[16]. 
 
IFNAR 1 
Interferon-α/β receptor (IFNAR) is a cell surface receptor composed of one chain with two 
subunits IFNAR1 and IFNAR2. IFNAR binds type 1 interferons together with Interferon α 
and β [17]. Type I interferons (IFNs) are cytokines with multifunctional activity that direct 
antiviral innate immunity virtually in all nucleated cells [18]. All type I interferons regulate 
their biological activity through a common receptor which is composed of the transmembrane 
proteins IFNAR1 and IFNAR2 (Figure 2). After the formation of a ternary complex, the 
interferon signals are transduced by receptor-associated Janus family kinases (JAK), which 
activate the STAT proteins. These in turn form homo and heterodimers that translocate to 
nucleus and directly regulate transcription of interferon responsive genes [19].    
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Figure 2:  Schematic view of the chromosome 21q22.11 class II cytokine receptor cluster: IFNAR2 
(interferon-α receptor-2), IL10RB (interleukin-10 receptor B), IFNAR1 (interferon-α receptor-1), 
IFNGR2 (interferon-γ receptor-2). Arrows indicate the direction of transcription and numbers indicate 
the distances between adjacent genes. Adapted and modified from Hardy et al. 2002 
 
Type I interferons (IFNs) play an important role in defense against viral infections and in 
modulating the adaptive immune system. In addition, they are capable of inducing a noticed 
antiproliferative activity. Type I interferon encoding genes, show polymorphisms in many 
diseases [20]. Protection or susceptibility against hepatitis B and C viruses, cerebral malaria 
and HIV are influenced by IFNAR polymorphisms [21,22,23]. Polymorphism of IFNAR1 
gene can cause impaired INFs signaling which may contribute in tumor progression and may 
lead to immune dysfunction which is widespread in cancer [24]. Two type I interferons Hu- 
IFN-αB2 and Hu-IFN-αF have been identified in Chinese hamster ovary cells which interact 
with splice variants [11, 25].  
 
IFNAR polymorphism is due to Variable Number Tandem Repeat (VNTR). VNTR is a region 
in the genome where a short nucleotide sequence is repeated tandemly (Figure.3). VNTRs are 
found in many chromosomes and vary in length between individuals. Analysis of VNTRs is 
another DNA amplification-based typing method. The number of tandem repeats of the 
analyzed locus can be enumerated by PCR amplification  using primers targeting the flanking 
regions and determination of resultant fragment length  [26]. This method is applied in 
different organisms from nonculturable bacteria to humans [27].  
 
Figure 3: Schematic diagram of VNTR with sequence of 32 nucleotides flanked by non-repetitive 
sequence. The lines symbolize non-repetitive sequence surrounding VNTR. Repetitive sequences are 
shown with rectangles. Sequence of each repeated fragment is the same as sequence shown on the top.  
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By recombination or replication errors individual repeats in VNTR can be removed or added. 
Non-repetitive sequences are the segments flanking to the repeats which allow the extraction 
of VNTR blocks by using restriction enzymes and amplification by using Polymerase Chain 
Reaction (PCR). The size of the each VNTR blocks can be verified by gel electrophoresis. 
There are two main classes of VNTRs: Microsatellites sequence repeats which are less than 5 
base pairs and Minisatellites which are with longer blocks up to 100 base pairs. The analyzed 
VNTR in the current study approximately consist of 32bp repetitions and located in putative 
enhancer of IFNAR1 gene [28]. The putative enhancer is present approximately 4kbp 
upstream of the IFNAR1 gene.  
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METHODOLOGICAL BACKGROUND 
Illumina SNP Genotyping 
Illumina SNP Genotyping arrays like Human660W-Quad® (660K beadchip), are used for 
detection of variations in DNA copy number (chromosomal aberration) across the genome, 
characteristically found in cancer [29]. The chromosomal aberrations in DNA copy number 
can inactivate tumor suppressor genes or activate oncogenes. Based on this, SNP genotyping 
can indicate deletions, duplications and amplifications which can be associated with cancer. 
Illumina SNPs array- Human660W-Quad® detects copy number changes by comparison of 
normalized intensity of signal (R) of a subject sample and a pool of reference samples. The 
basis for detecting chromosomal aberrations are genomic plots of the log2 (R subject / R 
reference) called log R ratio, and so called B allele frequency (BAF) value. Loss or gain of 
chromosomal material can be identified by measuring the intensities of signal in test DNA 
versus reference DNA which indicates the DNA copy number.  
 
POLYMERASE CHAIN REACTION  
PCR is a rapid and versatile in vitro method for amplifying a single or few copies of DNA to 
numerous copies of desired DNA fragments. This method includes thermal cycling which 
consists of repeated heating and cooling of DNA for melting and enzymatic activity of DNA 
polymerase in reaction mixture. PCR mixture consists of template DNA, MgCl2, PCR buffer, 
dNTPs (G, C, A, T), a pair of primers (forward and reverse) which enables selective and 
repeated amplification of template DNA and heat-stable DNA polymerase. dNTPs are 
molecules when joined together make up structural unit of DNA. 
Polymerase is an enzyme that catalyzes polymerization of dNTPs into a DNA strand and 
primers are short fragments that are complementary to template DNA and are designed so that 
they anneal at both ends of the DNA fragment that should be amplified during PCR. One 
primer is complementary to 5’ end and other primer is complementary to 3’ end of template 
DNA. PCR consists of three steps i) denaturation- in which double strand DNA become a two 
single strands ii) annealing- each primer anneals to one of the strands iii) elongation- this step 
depends on DNA polymerase, which synthesizes a new DNA strand complementary to 
template DNA by adding dNTPs in 5’ to 3’ direction. 
 
CLONING AND TRANSFORMATION 
Cloning is a process in which multiple copies of desired DNA fragments can be generated. 
The DNA fragment is inserted into vector by ligation, which is then linearized by using 
restriction enzyme. The DNA fragment is then incubated under suitable conditions with DNA 
ligase. The plasmid contains an antibiotic resistance gene (Figure.4). Following ligation, 
vector with insert is transformed into bacteria cells (E.coli) by transformation. The transfected 
cells are cultured in a medium containing antibiotics. The plasmid replicates along with 
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bacteria. The bacterial colonies are selected and the purified plasmid can be used for further 
studies. Bacteria cells are cultured on medium with antibiotics. This is a fact that only bacteria 
with antibiotic resistance gene will be able to grow. 
Figure 4: Map of plasmid from Invitrogene TOPO® TA® cloning kit (pCR®2.1-TOPO®) showing 
multiple cloning sites and with marked place of PCR-product ligation. The linearized vector supplied with 
in this kit has single overhanging 3’ deoxythymidine (T) residues. This allows the insert to ligate with the 
vector. (Adopted from http://f1000scientist.com/article/display/18015/) 
 
DIGESTION WITH RESTRICTION ENZYME 
The process of cutting DNA molecules into smaller pieces at the recognition site with specific 
enzymes like restriction enzymes or restriction endonucleases is called restriction digestion. 
These enzymes are able to cleave DNA molecules at specific positions (Figure.5).   
  
  
Figure 5: Specific restriction site of EcoRI enzyme restriction enzyme. The nucleotide sequence in the 
DNA contains recognition site (GAATTC) for EcoRI. EcoRI cuts DNA in both strands between the 
indicated nucleotides resulting in 5´ end overhangs (adopted from BC Decker Inc, 2000). 
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Restriction enzymes are classified into three general groups Types I, II, III and IV based on 
requirements of enzyme cofactor, composition, and nature of their target sequence, position of 
their DNA cleavage site relative to target sequence [30]. Restriction enzymes first were 
isolated from bacteria and now there are several types of synthesized restriction endonuleases 
which cut DNA differently  [31]. For example EcoRI enzyme recognizes and cuts sequence 
GAATTC which is a palindrome as a complementary sequence CTTAAG. It creates sticky 
ends that have T (Thymine) overhangs at their 5’ ends and bind to the DNA products that 
have A (Adenine) overhangs at their 3’ ends (Figure.5). Sites where enzyme cuts are called 
restriction sites and they are typically four, six, eight, ten or twelve nucleotides long. Plasmids 
contain dozens of restriction sites. This allows inserting of any DNA fragment into plasmid 
vector which can be later replicated with bacteria cells. After restriction digestion length of 
DNA fragment can be analyzed by gel electrophoresis. 
SANGER SEQUENCING 
The sequencing determines order of nucleotides in DNA or RNA molecule. In 1974, two 
methods “Chemical cleavage protocol” by Maxam and “dideoxy sequencing or chain 
termination” by Sanger were developed  [32].  Sanger’s method became standard method 
because of its practical similarity to natural DNA replication process  [33]. The dideoxy 
sequencing or chain termination is based upon use of ddNTPs in addition to normal dNTPs 
present in the DNA. The ddNTPs are similar to normal nucleotides but differ in the 3’ carbon 
and they contain a hydrogen group instead of hydroxyl group (Figure 6). During synthesis of 
DNA the dideoxynucleotide is added to new DNA strand, next nucleotide cannot be added 
because ddNTPs are lacking 3’ hydroxyl group on their deoxyribose sugar. Due to this reason 
ddNTPs are called as chain terminators. 
 
 
Figure 6: Schematic diagram of deoxynucleotide and dideoxynucleotide. Arrows indicates the single 
difference in the structures of the two molecules in 3’ carbon. 
In Sanger sequencing one primer which is complementary to the template DNA, four dNTPs 
and four ddNTPs in lower concentration than normal dNTPs concentration are used. Before 
sequencing, DNA has to be initially denatured. To one of template strand the primer is being 
annealed. The primer or nucleotides are fluorescently or radioactively labeled as final product 
has to be detected on gel or capillary.  
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 AIM 
Identification and comparison of copy number variants in IFNAR1 loci of healthy uninvolved 
margin of breast tissue surrounding primary tumour and blood derived-DNA from the same 
patient by using Illumina SNPs array-Human660W-Quad®. To confirm this we have carried 
out PCR, cloning and sequencing. The long term aim of the project is to investigate genetic 
variations occurring in enhancer region 4kb upstream of IFNAR1 loci whether these factors 
influence the development of cancer and if there is link between the predicted enhancer region 
mutation and disease susceptibility. 
 
 
 
 
 
 
 
 
 
 
 
15 
 
MATERIALS AND METHODS 
Sample acquisition 
DNA samples from the blood and healthy uninvolved margin were acquired from breast 
cancer patients via collaboration with Oncology Center in Bydgoszcz, Poland. These samples 
were genotyped using Illumina SNPs array- Human660W-Quad® at University of Alabama at 
Birmingham. The raw data was analyzed using the Nexus software (version 4).  
PCR 
PCR amplification was carried out in 25 μl containing final concentrations of template DNA 
(5 ng/μl), (0.4 μM) of each primer, (0.04 U/μl) of Platinum Taq DNA polymerase 
(Invitrogen), dNTPs (0.04nM) (Fermentas), 2.5 μl Stofell Buffer (Invitrogen), MgCl2                       
(2 mM) (Invitrogen) and H2O. 
PCR was carried out using the following program: Initial denaturation at 95°C for 4 min; 
amplification for 35 cycles for 30 sec at 95°C, 30 sec at 64°C and 1 min at 72°C; and a final 
extension for 10 min at 72°C in a programmable thermal controller (MJ Research Inc). The 
sequence of primers is shown in table1.  
Primer Sequence (5´- 3´) Product length (bp) 
Fwd blue primer 
(STSG607079 L)  
 
CCTAACAGCTGGATAGATTGCC 
 
          416 
Rev blue primer 
(STSG607079 R)  
 
 
CCATGCGTGTATATTCCATACG 
 
          416 
Table. 1: Primes used for PCR 
  
Gel Electrophoresis 
The PCR products were analyzed on 1% agarose gel with 1xTAE to measure their size. 
Approximate 8 μl of PCR product and 2 μl of loading buffer were added to each well. The 
electrophoresis was set at 120 voltes for 1 hr. The band size was verified with 1kb ladder 
(GeneRulerTM ).   
 
Cloning of PCR Products with plasmid pCR®2.1-TOPO® vector and Transformation 
Using One Shot® MAX Efficiency® DH5α-T1R Chemically Competent cells 
The PCR fragments were cloned using One Shot® DH5α Competent Cells (Invitrogen) which 
has maximum efficiency. The following steps were carried out for cloning. 
To carry out subcloing 2 μl of PCR product was taken to setup the reaction mixture (see table 2).  
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Reagents Amount (μl) 
PCR product 2 μl 
Salt solution 2 μl 
Sterile H2O 1 μl 
TOPO vector 1 μl 
Total 6 μl 
Table 2.  Composition of reaction mixture according to Invitrogen TOPO-TA Cloning kit manual.  
The reaction mixture was gently mixed by pipetting up and down several times and incubated 
at room temperature for 26 min. After incubation the reaction mixture was kept on ice.  
2 μl of reaction mixture was added to One Shot® MAX Efficiency® DH5α-T1R Chemically 
Competent E. coli cells (Invitrogen). The reaction mixture was incubated on ice for 20 min 
followed by heat shock for 30 sec at 42 °C in a water bath and immediate incubation on ice 
for 2 min. 250 μl of SOC medium was added to reaction mixture which was then placed on a 
shaker at 160 rpm for 1 hr at 37 °C.  
To each LB-agar plate containing the antibiotic kanamycin (Sigma) 50 µg/ml, 83 μl of 
transformation mixture was added and spread with a sterile L-shaped plastic rod and 
incubated for overnight at 37°C. 40 single selected colonies were picked from LB-agar plates 
with a tip. Each clone was added to 5 ml of LB with kanamycin and incubated in a shaker for 
overnight at 37°C at 250 rpm.  
 
Plasmid DNA purification 
Prior to purification of plasmid 1 ml of culture was mixed with 200 μl of glycerol stored at -
70°C for further use. Plasmid DNA was purified by using the QIAprep Spin Miniprep Kit, 
according to manufactures protocol (QIAGEN). The culture medium was added to 2 ml tubes 
and centrifuged at 10000 rpm for 3 min in micro centrifuge. Supernatant was discarded; to the 
pellet 250 μl of P1 buffer (Resuspension Buffer) was added and resuspended by vortexing. 
Then 250 μl P2 buffer (Lysis buffer) was added and mixed thoroughly by inverting the tubes 
for several times. Buffer P2 was used to lyse bacterial cell membrane to release DNA. 350 μl 
of N3 (Neutralization Buffer) was added and mixed thoroughly by inverting the tubes 4-6 
times until the solution became viscous and cloudy. The tubes were centrifuged at 17400 rpm 
for 10 min. Supernatant was loaded to QIAprep spin column by pipetting and centrifuged for 
1 min and follow through was discarded. The column was washed with 750 μl PE buffer 
(Wash Buffer) and centrifuged for 1 min, flow through was discarded and centrifuged for 
additional 1 min to remove the residual wash buffer. Later, 120 μl of water was added to 
column and let it stand for 1 min. Elution was performed by centrifuging for 1 min. The 
concentration of extracted DNA was measured by spectrophotometer (NanoDrop). 
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Confirmation of insert existence and Gel electrophoresis 
By using EcoR1 restriction enzyme, insert was cut out from plasmid. The composition of 
reaction mixture was as shown in  table 3.  
Components Volume (μl) 
EcoR-1 buffer 1 μl 
EcoR-1 enzyme 1 μl 
Plasmid DNA 8 μl 
Total 10 μl 
Table 3. Composition of restriction digestion reaction mixture. 
500 ng of plasmid DNA with 20 000 U/ml of EcoR1 enzyme (Bio Labs) and 1 μl of 10x 
EcoR1 Reaction Buffer (Bio Labs) was incubated in a thermocycler to carry out restriction 
digestion and program was set at 37°C 1 h; 65°C 20 min; 8°C ∞. 
Digested plasmid DNA was run on 1% agarose gel at 120V for 2 hrs by using xylene loading 
dye. The fragments with different insert length were chosen for sequencing.   
 
Sanger Sequencing 
Plasmids with different insert lengths were chosen for sequencing. Each plasmid was 
sequenced in triplicates with eight primes (Table 4).  
                      Primer Sequence (5´- 3´) 
ORANGE_F GAATCGCTTGAACCCGGAAGG 
BLACK_F CCTGGGTAACACAGCGGAAATCC 
M13_R CAGGAAACAGCTATGAC 
LF4_F GTTGTGGTGAGCCGAGATCG 
JD3_F CAGGAGAATCGCTTGAAC 
JD4_R AATATATACGTATGGAATATA 
M13_F CAGGAAACAGCTATGAC 
LF3_R AGTATGGAATATATACGTAT 
Table 4. Primes used for sequencing reaction.    
To 96 well plates, 12.5 ng/µl template DNA and 1.6 pmol/µl of each primer in triplicates was 
added. Plate was spin down for few seconds at 700 rpm followed by initial denaturation at 
95oC for 5 minutes in thermocycler. Meanwhile BigDye termination reaction mixture was 
prepared as follows shown in table 5.   
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Reagents Volume (µl) 
BigDye Terminator 3.1 4 µl 
SD-buffer 2 µl 
MQ H2O 1 µl 
Total 7 µl 
Table 5. Composition of sequencing reaction mixture according to Applied Biosystems BigDye terminator   
3.1 Cycle Sequencing kit manual. 
 
After initial denaturation of plasmid DNA, sample was cooled on ice and to each well 7 µl of 
BigDye terminator reaction mixture was added. The Plate was spin down for a few seconds 
and was placed in thermocycler with a standard sequencing program as shown in table 6. 
 
Temp oC Time  No. Cycles 
95 30 sec  
94 25 sec  
35  50 15 sec 
60 2 min 
8 Forever  
                            Table 6. Sequencing program  
After sequencing program, samples were precipitated as follows, 1 µl of 125 mM EDTA pH 8 
and 1 µl of 3 M sodium acetate pH 5,4 were added to each well. The plate was spin down for 
a few seconds to ensure that solutions get to bottom of wells. Later 29 µl of 95% ethanol was 
added to each well; plate was vortexed briefly and incubated in room temperature for 15-
minutes in dark. After incubation samples were centrifuged at 1750 g for 45 minutes at 4oC. 
After precipitation the reaction mixture was removed by inverting the plate upside down and 
spin down at 300 rpm for 30 sec. Later 70 µl of 70% ethanol was added to each well to 
remove residual impurities. The plate was vortexed briefly and centrifuged at 1750 g for 15 
minutes in 4oC. Ethanol was removed from wells by spinning the plate in inverted position at 
700 rpm for 30 seconds and the plate was left for 15 minutes at room temperature to air-dry. 
As ddNTPs present in BigDye Terminator 3.1 are light sensitive, plate was protected against 
light during whole procedure. Pellets of sequencing reaction were solved in 10 µl of HiDi 
Formamide (Applied Biosystems P/N 4311320) and submitted to Uppsala Genome Center 
(UGC) core facility in order to conduct capillary electrophoresis of samples. The results of 
capillary electrophoresis was assembled and aligned with CodonCode Aligner software. 
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RESULTS  
Illumina  
DNA samples from the blood and healthy uninvolved margin that was acquired from breast 
cancer patients was genotyped by Illumina SNPs array- Human660W- Quad® at University of 
Alabama at Birmingham. The results from Illumina and data analysis from Nexus software 
for blood and uninvolved margin of breast tissue show deletion in healthy uninvolved margin 
of putative enhancer region 4kb upstream of IFNAR1 gene of two samples SK58B, KJ42B 
surrounding primary tumor when compared to SK58K, KJ42K of blood derived DNA. 
(Figure 6)  
 
 
Figure 6: The data analyzed from Illumina SNPs 660W array using Nexus Software of two SNPs in 
KJ42B and KJ42K Breast cancer patients. On y axis Log R ratio value, indicates measured intensity of 
signal in reference to signal from pool of reference samples and on x axis SNPs places on chromosome 
shown in megabase pairs. In both patients we can see deletion of some SNPs in B samples compare to the 
same SNPs in samples K, which was used as a reference, marked with arrows. B refers to DNA derived 
from Healthy uninvolved margin and K refers to DNA derived from blood. 
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These results suggest there is difference between CNVs in blood and uninvolved margin of 
breast tissue surrounding primary tumor. These results were confirmed later by cloning and 
sequencing.  
Gel electrophoresis  
Based upon the results from Illumina the samples (KJ42K, KJ42B and SK58K, SK48B) was 
amplified by using primes (table.6) and gel image shows an expected band around 1.4kb in 
the upstream of IFNAR1 loci (Figure 7).  
 
Figure 7: the amplified PCR products of (KJ42K & KJ42B), (SK58K & SK58B) show a band of 
fragment length around 1.4kb  
 
Restriction digestion and gel electrophoresis 
The results from the Illumina confirmed the presence of variation in the samples SK58B and 
KJ42B DNA derived from the uninvolved margin compared to SK58K and KJ42K DNA 
derived from the blood of the same patient (Figure 8 & 9). 
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Figure 8: Gel image showing first ten clones on the left are from sample SK58B and the next ten clones are from 
SK58K. In sample SK58B clone number 2 indicated by arrow shows variation in fragment length which is not 
presented in any clone of SK58K.  
 
 
Figure 9: Gel image shows  clones numbered from 33 to 40 on the left are from sample KJ42K, showing two variations 
in length, clone number 33, 34, 35, 39 & 40 around  1400kb and in KJ42B clone number 34 shows variation in size 
around 1400bp compared to other clones 33,35,36,37,38,39 & 40.  
 
 
Sequencing  
The sequencing results showed presence of three or two different variants in clones from 
sample SK58B and SK58K respectively (Table6). The fragment length was analyzed by 
codoncode analyzer for SK58B and SK58K confirmed presence of different fragments 
lengths in SK58B and two different fragments in SK58K in which one clone is similar to 
SK58B as shown in the table (7). 
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Sample Clone No. Length in bp  
(by codoncode aligner) 
SK58B 1 
2 
3 
1151 
710 
633 
SK58K 1 
5 
633 
1150 
Table 7: Length of clones analyzed with codoncode software. Sample SK58B showed three clones with 
different sizes and in sample SK58K two clones with different sizes.  
The results after sequencing reaction of clones from samples SK58K and SK58B was 
concordant with gel images. The sequencing reaction was carried out for clone number 33 and 
38 from sample KJ42K which shows different sizes on the gel. The obtained result confirms 
the presence of two different fragments (Table 8). 
 
Sample Clone No. Length in bp (by codoncode 
aligner) 
KJ42K 33 
38 
1119 
633 
Table 8: Size of the clones from based on condoncode aligner.  Clone 33 and 38 showed different 
sizes. 
 
As per the results observed, fragments analyzed in the study show variation in size due to 
presence of VNTRs of 32 repeats with the sequence ATATGTGGAACCAATACATATAT
GCAACATAT. It also confirms the presence of CNVs in the IFNAR1 loci of uninvolved 
margin of the breast tissue surrounding the primary tumor. These variations in the gene may 
lead to the development of the disease.  
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DISCUSSION 
The results from few decades in progression of breast cancer explain <10% of all cases [34, 
35].  In this study in a set of few breast cancer samples, a remarkable variation was found in 
the region connected to IFNAR1 gene by using Illumina SNPs array- Human660W-Quad®. 
This variation in putative enhancer region of IFNAR1 loci may lead to conflict in gene 
expression and can guide to disease development [36,37]. To assess if this polymorphism in 
IFNAR1 gene was related to breast cancer, region was studied by using PCR, subcloning, 
restriction digestion and sequencing. The genotyping data, gel images of the digested 
fragments and sequencing showed same results, which indicates presence of CVNs in 
uninvolved margin of breast tissue surrounding primary tumor and blood of same patient in 
the study. But results do not specify that the variation in VNTR region leads to development 
of breast cancer development.      
Characterizing changes in DNA copy number is of huge importance in understanding 
tumorigenesis. While investigating genomes of breast cancer patients from Illumina analysis, 
numerous genetic variations were identified in the form of tandem repeats in few numbers of 
samples. The study shows that polymorphism in variable number of tandem repeats of insulin 
gene in promoter region plays an important role in modulating insulin transcription 
and diabetes susceptibility [38]. Other findings also recognized role of insulin gene 
polymorphism in pancreatic carcinogenesis as well as in tumor staging [39]. These studies 
stress that pathogenic potential of VNTRs not only in size but also in its sequence.  
 
The genetic modifications identified in breast cancer might be associated with IFNAR1 gene. 
There is no much published data about VNTR polymorphism of IFNAR1 gene related to 
breast cancer.  In this study genetic alteration was identified approximately 4kb upstream of 
IFNAR1 gene. But this does not appear in all investigated samples in correlation with breast 
cancer development. However there is genomic imbalance in this region because these 
aberrations seem to be frequent in numerous cohorts of cancer patients. 
 
Nevertheless, presence of somatic mosaicism was found. The presence of more than one 
genetically distinct lineage of somatic cells in a single organism is called somatic mosaicism. 
These variations arise de-novo and thus will occur typically only in a few cells. Indeed, 
present hypothesis in origin of cancer state that, accumulation of somatic mutations leads to 
unregulated cell division [40].  
It is to be expected that rate of discovery for short somatic variations (i.e. CNVs) that are 
present in small proportion of studied cells will continue to accelerate and studies on genetic 
heterogeneity of breast malignancies create great opportunities for finding novel biomarkers 
for the disease progression in breast cancer. 
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 FUTURE PERSPECTIVES 
A large number of samples, showing polymorphism in putative enhancer region of IFNAR1 
gene of uninvolved margin of breast tissue surrounding primary tumor consent to validate 
expression level of the gene. These results may show if there is any variation in this region 
which affects the features of the gene.  
Development of new methods and already existing techniques allowing analyzing more 
samples in shorter period of time may contribute to investigations at larger scale (e.g. parallel 
sequencing) and less cost effect. Several studies demonstrated greater number of aberrations 
found in primary tumors than in matched metastases [41]. However, these findings demand 
further investigation. 
Studies related to metastasis research in breast cancer are not well developed. Investigations 
that could compare genetic profiles of primary tumor and uninvolved margin may lead to 
identification of genomic abreactions in relation to cancer development. On other hand 
widening the studies on mechanism of metastasis in breast cancer may help in development of 
new drugs and early diagnostic tests.    
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